Study results spark 13% drop in Perspective Therapeutics shares – Radiation levels in focus
Shares of Perspective Therapeutics (NYSE AMERICAN: CATX) fell sharply, dropping over 13% to $11.49, after the latest data from their Phase 1/2a study on a melanoma treatment yielded mixed results. Analysts and investors reacted to the company’s announcement that lower doses of the radiopharmaceutical [212Pb]VMT01 were more effective compared to higher doses, while an unexpected […]